These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34452870)

  • 1. Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer.
    Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; McKay RR
    Clin Genitourin Cancer; 2021 Dec; 19(6):564.e1-564.e10. PubMed ID: 34452870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
    Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
    J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.
    Nørgaard M; Bjerre MT; Fredsøe J; Vang S; Jensen JB; De Laere B; Grönberg H; Borre M; Lindberg J; Sørensen KD
    Clin Chem; 2023 Apr; 69(4):386-398. PubMed ID: 36762756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
    Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
    Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
    EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
    Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
    Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform.
    Lin E; Hahn AW; Nussenzveig RH; Wesolowski S; Sayegh N; Maughan BL; McFarland T; Rathi N; Sirohi D; Sonpavde G; Swami U; Kohli M; Rich T; Sartor O; Yandell M; Agarwal N
    Oncologist; 2021 Sep; 26(9):751-760. PubMed ID: 34157173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.